Biocytogen Pharmaceuticals (Beijing) (HKG:2315) expects a net profit of between 27.3 million yuan and 37.3 million yuan for the year 2024, compared with a loss of around 383 million yuan a year prior, a Friday filing with the Hong Kong bourse said.
The pharmaceutical company attributed the anticipated turnaround to profit mainly to a higher sales revenue from the antibody discovery business, a higher revenue contribution from the gene editing animal model business, and a significant decline in R&D investment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.